The cost implications of a polypill for primary prevention in the TIPS-3 trial.
Andre LamyWesley TongPhilip JosephPeggy GaoPrem PaisPatricio López-JaramilloMarjan Walli-AttaeiAntonio Miguel DansDenis XavierShamim TalukderAnwar SantosoHabib GamraSalim YusufPublished in: European heart journal. Quality of care & clinical outcomes (2022)
The use of a polypill (CES) in TIPS-3 increases costs in lower-middle-income countries and upper-middle-income countries but is affordable in countries at various economic levels and is cost neutral (dominant) in high-income countries.